Implantation of an adjustable gastric band is a frequently performed procedure to treat morbid obesity. One drawback of this restrictive bariatric procedure might be that subjects tend to eat a fat enriched liquid diet, which might prohibit further weight loss. Orlistat, a newly developed intestinal lipase inhibitor, prevents about one third of ingested fat to be absorbed. Whether patients no longer loosing weight after implantation of an adjustable gastric band and not tolerating further band restriction might weight after addition of Orlistat therapy is unknown.
To investigate this question 38 patients 18 AE 6 months (mean AE SD) after implantation of an adjustable gastric band and no longer loosing weight 3 months before initiation of the study were included. Subjects were divided in 2 groups which were matched for age, sex, ®lling volume of the adjustable band, body mass index (BMI) at time of surgery and at time of initiation of study, i.e. 18 AE 6 months after SAGB-implantation. Patients of group A received dietary counseling and Orlistat 120 mg TID for 8 months while subjects of group B received only dietary counseling with respect to fat intake. During the following eight study months subjects of group B lost an additional 3 AE 2 kg, whereas subjects of group A lost 8 AE 3 kg (Group B, p`0.01, months 18 vs. 26 of study; p`0.03, Goup A vs B). Only minor gastrointestinal side effects were encountered in subjects on Orlistat therapy. Follow up of patients after the end of the 8 months study are summarized
Ef®cacy
Intention to treat (n 354) Completers (n 295) below. 4 patients received an additional distal gastric bypass and 3 took their Orlistat on a irregular basis. Therefore these 7 patients were excluded from the poststudy analysis. 8 of the 19 patients initially assigned to Orlistat treatment continued their treatment with Orlistat TID for an additional 3 months. Weight at 26 months was 88.8 AE 2.9 kg and remained stable throughout the next three months (month 29: 88.0 AE 3.9 kg). 4 subjects stopped their Orlistat therapy. Again weight remained stable during the next three months of observation (month 26: 88.0 AE 7.0, month 29: 88.3 AE 7.2 kg).
In conclusion, the present results although not obtained in a randomized placebo controlled fashion suggest that patients with gastric banding no longer loosing weight for several months should be offered Orlistat therapy for at least 8 months. Using this therapeutical approach it might well be that the frequency of additional bariatric malabsoprtive procedures can be reduced. Further randomized, placebo controlled studies and a longer follow up are needed to de®ne the exact value of Orlistat therapy in patients with gastric banding in the future.
INTRODUCTION:
Basic neurophysiological and neurophamacological studies have demonstrated a role for serotonin (5-HT) in the regulation of appetite, satiety and control of body weight. In these experiments we have tested the effect of citalopram, a selective serotonin reuptake inhibitor (SSRI) on food intake, weight increase, and blood glucose levels in young obese hyperglycemic mice (Umea Ê obaob). Obaob-mice have a defect leptin resulting in hyperphagia, hyperglycemia and increased body weight when compared with normal mice. METHODS: Citalopram was dissolved in saline and given i.p (10 ± 30 mgakg body weight) starting at 3 weeks of age. The dose was increased stepwise with the highest dose given from 11 weeks of age. Some animals were injected from 10 weeks of age with 0, 10 or 20 mgakg citalopram daily for a period of 9 weeks. RESULTS: Citalopram had no effect on weight increase in 3 ± 10 week's old obaob-mice when the weight increase was most rapid. Citalopram reduced the weight increase during the age 10 ± 19 weeks. There was a rise in food intake in all animals after weaning at three weeks. Food intake reaches a maximum at 7 ± 10 weeks of age and then declines. The reduction was more rapid in citalopram treated mice. The weight of faeces paralleled the food intake. Citalopram treatment had no effect on serum insulin levels in 15 week's old mice. Blood sugar values in fed mice reached a peak at 7 weeks of age (21.7 AE 1.7 mmolal in controls and 22.3 AE 1 mmolal in citalopram treated mice). After that blood sugar values decreased to 16.8 AE 2.1 mmolal at 15 weeks in controls, and to 13 AE 11 mmolal in citalopram treated mice (P`0.01). There was a close correlation between accumulated food intake and blood glucose values in individual animals. Obaob mice are infertile because of the leptin de®ciency. This was not corrected by citalopram treatment. Obaob mice have a high b-cell proliferation rate at 3 ± 10 weeks of age, and they have large islets of Langerhans. This was not affected by citalopram treatment. CONCLUSIONS: Our ®ndings show that direct effects of leptin cannot be reproduced by increased serotonergic tone, but some of the indirect metabolic aspects of leptin de®ciency can. We ®nd that feedef®ciency in terms of weight increase in relation to food intake is the same in controls and citalopram treated mice. This suggests that citalopram reduced food intake but had little effect on the metabolic ef®ciency. The serotonergic system therefore probably plays a role as a regulator of food intake over shorter time periods, also in the absence of leptin.
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Initial weight loss response to sibutramine predicts 2 yrs outcome in STORM We used the European multi-centre STORM trial to identify predictors of 6 and 24 months weight loss success (1). 605 obese patients were treated for 6 mo with sibutramine (S) 10 mgad combined with a 600 kcalad de®cit diet. 467 patients (77%) with b 5% weight loss were randomized 3:1 to S and placebo (P) for 18 mo weight maintenance. Mean 6 mo weight loss was 711.3 kg, after 2 yrs the P group regained to 75.2 kg and the S group regained to 710.4 kg. Predictors of weight loss were analysed in completers. Among patients who had lost b 1 kg after 1 mo, 56% achieved b 10% weight loss after 6 mo, whereas only 7% of those who lost`1 kg achieved this target (P`0.001). 47% of patients losing b 1 kg completed the 2 yrs program, compared to only 8% of those who lost`1 kg (P`0.05). A goal of 15% weight loss at mo 6 was reached by 22, 24 and 29% of the patients losing 1, 2, 3 kg respectively in the ®rst month, but by only 0, 2 and 3% of patients who lost`1,`2,`3 kg (p`0.05). Patients losing 2 kg during the 1st mo on S were 76% more likely to lose 5% at mo 6 than patients who failed to achieve this initial target; odds ratio 1.76 (95% CI: 1.26 ± 2.45). We have previously shown that pretreatment predictors can explain only 8% in the variation of long-term weight loss (2). By contrast, the present results indicate that very early weight loss in response to sibutramine and diet is a very useful clinical indicator of future therapeutic success. Sibutramine (SIB) acts centrally in the brain and provides long-term control of weight when included with a weight management program. A meta-analysis of 6 long term clinical studies was carried out to compare the weight loss observed when combining SIB treatment or placebo (PLA) treatment with a weight-loss program. Each of the 6 studies was randomized and placebo controlled. A total of 1121 obese subjects (BMI ! 30 mgakg 2 ) received SIB 15 mg qd, taken at any time during the day, for 12 months. SIB was generally combined with a program consisting of a total calorie reduction of 20% plus 30 minutes of additional exercise (3 walksaday). Meta-analysis was performed according to the method of Whitehead and Whitehead. The weight loss was signi®cantly greater in subjects whose weight-loss program included SIB as compared with placebo. During the 12 months of all studies included in the meta-analysis, SIB was safe and well tolerated. In conclusion, when included in a reduced calorie diet and exercise weightloss program, SIB produces greater weight loss (P`0.001) and 3-to 5-fold more responders as compared with diet, exercise program and placebo. In addition, during the 12 months of the studies, weight regain was prevented.
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An approach to anti-hypertriglyceridemia and anti-obesity drugs of campest-5-en-3-one
, T Shimizu 2 , T Nakata 2 , M Tanaka 1 gated. We ®nally obtained campest-5-en-3one, 1 as a candidate compound for development. Plasma triglyceride and free fatty acids (NEFA) of SD rats were signi®cantly decreased by 0.1% and 0.3%, respectively, on dietary exposure to campest-5-en-3-one. Signi®cant inhibition of body weight of SD rats was also observed with 0.3% dietary exposure to this chemical. In ICR mice, clear effects on triglyceride and NEFA in the plasma and on fat weight in the abdominal cavity were observed. However, the chemical showed no effect on plasma cholesterol concentration in either animal.
When campest-5-en-3-one was fed to ICR mice, marked inhibition of chylomicron formation and accumulation of lipids were observed in the jejunal mucosal cells of the animals. As a result, the jejunum weight and the amount of lipids determined in the tissue fraction of the jejunum showed time-dependent increases, but recovery of the jejunum weight was possible by feeding of the control diet. The compound has no activity on microsomal triglyceride transfer protein (MTP) inhibition.
In intravenous administration of campest-5-en-3-one on SD rats, no abnormalities were observed on autopsy or in measurement of serum ALT up to a dose 180 mgakg (60 mgakgÂ3 days). Care must be taken to avoid de®ciencies in fat-soluble vitamins such as A, D, E and K. A 0.3% dietary exposure in animals corresponds to 2.0 g per day per 2,500 kcal of human caloric intake.
The results of ef®cacy, mode of action and toxicity studies suggested that this compound is quite promising as drugs to treat hypertriglyceridemia and obesity.
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Early response to orlistat predicts 10% weight loss at 6 months in obese patients with comorbidities B Guy-Grand Weight loss (WL) ! 5% of initial weight (early response, ER) 3 months after start of orlistat is required for continuing the drug. This six month multicenter double blind study included 1004 obese outpatients (18 ± 65 y., BMI 28 ± 40 Kgam 2 ) with treated hypercholesterolemia, type 2 diabetes or hypertension. Patients were randomized to orlistat 120 mg t.i.d. (O) or placebo (P) both combined with a mildly reducedcalorie, reduced-fat diet. At baseline, O and P groups were not signi®cantly different. At 6 months, weight loss was ! 5% in 48% (O) vs 16% (P) (p`0.001), and ! 10% in 18% (O) vs 5% (P) (p`0.001). At M6 ER lost 710.3 AE 4.7% weight vs 73.1% AE 3 non ER(p`0.001). 99% (319a323) of non ER did not achieve ! 10% WL at M6. 96% (86a90) of patients who lost ! 10% weight at M6 were ER. Weight loss in ER and non ER groups is described below:
Predictive value of ER was : positive: 51%, negative: 99%, Sensibility: 80%, Speci®city 96%. Early response is a predictor of 10% weight loss at 6 months with orlistat in obese and overweight patients with comorbidities.
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Chitosan as an adjunct to dietary treatment of obesity The aim of the present study was to verify the clinical ef®cacy and applicability of chitosan as a possible adjunct in the treatment of obesity. METHODS: Supplementation of a low calorie diet (1000 kcaladay during 6 months) with chitosan was evaluated in a randomised, placebo-controlled, double-blind study. Fifty obese women (BMI b 30) participated in the study. In the chitosan group, participants received 750 mg pure chitosan tablets (from Primex Ingredients ASA, Avaldsnes, Norway), two tablets three times daily before each main meal. The placebo group received identical placebo tablets containing lactose and microcrystalline cellulose. RESULTS: Signi®cantly higher body weight loss and a greater decrease of systolic and diastolic blood pressure was noted in the chitosan-supplemented group. There was no group difference in the decrease of LDL and total cholesterol among these obese but normolipemic participants. No adverse effects were noted but the number of drop-outs was greater in the placebo group than in the chitosan group. After six months of treatment, the body weight decrease was 15.9 kg and the body fat decrease 12.3 kg in the chitosan group and 10.9 kg and 7.4 kg respectively in the placebo group. No group difference in the decrease in fat free mass was noted. In the chitosan group, systolic blood pressure decreased by 13 mm Hg after 3 and by 19 mm Hg after 6 months of treatment. In the placebo group, the corresponding values were lower 74 mm Hg after 3 and 9 mm Hg after 6 months of dietary treatment. CONCLUSION: It is concluded that chitosan can be used as a valuable and safe adjunct in the long-term dietary treatment of obesity. Chitosan seems to accentuate the reduction of blood pressure associated with weight reduction. The magnitude of the hypolipidemic effect of chitosan is strongly dependent on the molecular weight, degree of deacytelation purity and viscosity of the chitosan preparation used and no de®nite effect could be observed in this study.
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Lack of effects of¯uoxetine on orexin immunostaining in the obese Zucker rat hypothalamus Orexin-positive neural cell bodies are present in the lateral hypothalamus and project to several brain regions where orexins may act as neuromodulators through its action on speci®c receptors and mediate appetite and other behavioral functions in rodents. Due to the fact that anorexigenic effects of uoxetine have been described in rodents after chronic administration of uoxetine, the aim of the present work was to describe the effects of this drug on orexin immunostaining in the obese Zucker rat hypothalamus. 6 weeks old faafa Zucker rats (n 6) were subjected to daily intraperitoneal injections of¯uoxetine chlorhydrate (10 mgakg), for two weeks. The control group (n 6) was given 0.9% NaCl solution in the same volume and duration as the experimental group. 50 micrometer brain sections were immunostained for orexin A or orexin B by the avidinperoxidase technique and the numbers of positively stained neural cells were measured with the aid of a computerized image analysis system. Fluoxetine administration signi®cantly decreased food intake (26%, P`0.01) and body weight (53.7%; P`0.001). No changes in the number of neural cells inmunostained for orexin A were observed in the lateral hypothalamic area, perifornical region and paraventricular nucleus of the obese Zucker rat hypothalamus after¯uoxetine treatment with respect to controls, and similar results were observed for orexin B immunostaining. These results suggest a lack of involvement of these peptides in the anorexigenic mechanism of this drug.
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INTRODUCTION:
Sibutramine is a new centrally acting weight lowering drug which enhances satiety and increases energy expenditure. The aim of the present post-marketing surveillance study (PMSS) was to evaluate ef®cacy and safety of sibutramine in obese subjects, BMI ! 27 kgam 2 , under primary care conditions in Germany. METHODS: The PMS-Study was conducted using everyday routines prevailing in private practices. Formal dietary or behaviour modi®cation programmes were not applied. The dosage of 10 mg sibutramine could be increased after 4 weeks to 15 mg, the observation period was 12 weeks. RESULTS: A total number of 6360 obese subjects were included. On average weight decrease was 10 kg from 98,4 AE 17,7 kg to 88,4 AE 16,2 kg after 12 weeks.
Metabolic parameters were positively in¯uenced. A favourable in¯uence of the sibutramine treatment was also seen for the blood pressure. Systolic blood pressure decreased from 140 AE 24 mm Hg to 133 AE 13 mmHg and diastolic blood pressure from 86 AE 31 mmHg to 81 AE 15 mmHg. Tolerability proved to be very good with just 1,8% of patients reporting adverse events. CONCLUSION: Sibutramine, administered to a typically obese population under primary care conditions results in signi®cant weight loss and improvement of cardiovascular risk factors.
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Pegylated human recombinant leptin causes additional weight loss and affects LH levels in energy-restricted mildly obese men Starvation induces a complex neuroendocrine response in humans as a defence mechanism. It is suggested that the decrease in leptin is an important signal to trigger this adaptive metabolic response Ã . To explore this question, a randomized, double-blind, placebocontrolled study was executed to investigate whether elevated leptin levels using long-acting pegylated human recombinant leptin (PEG-OB) in¯uenced adaptive physiological responses to semistarvation induced by a VLCD (2 MJaday) in 24 healthy male subjects (mean AE SEM; 34.8 AE 0.9 yr, 96.1 AE 1.8 kg, BMI 28.8 AE 0.3). PEG-OB was well tolerated based on adverse event reports, lab values and vital signs. Weekly s.c. administration of 80 mg PEG-OB led to signi®cant (p`0.03) additional weight loss (14.6 AE 0.8 vs 11.8 AE 0.9 kg) and reduction in appetite (p`0.05) after 6 weeks of treatment and energy restriction but did not affect changes in body composition, Resting Metabolic Rate, glucose tolerance and blood metabolites. Furthermore, a signi®cant relationship between the change in mean LH levels and PEG-OB treatment when corrected for weight loss was demonstrated. PEG-OB treatment did not reverse the fasting-induced changes in the thyroid, corticotropic, somatotropic axes and sympathetic nervous system activity. These results support the recent hypothesis Ã that the main physiological functions of leptin in humans are stimulating appetite and suppressing reproductive function during starvation. Ã Flier JS. 1998 J Clin Endocrinol Metab 83:1407 ± 1413.
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Randomised trial of the effect of orlistat on body weight and CVD risk pro®le in overweight and obese patients with co-morbidities 2 ) with one of the following risk factors were eligible for inclusion: impaired glucose tolerance, hypercholesterolaemia andaor hypertension. After screening, patients entered a 2-week single-blind placebo lead-in period during which they followed a mildly reduced-calorie diet before being randomised to double-blind treatment with either orlistat 120 mg or placebo three times daily in conjunction with dietary intervention for one year. The study was conducted at 54 primary care centres and 12 secondary care diabetes clinics in the United Kingdom. RESULTS: A total of 737 obese adults were enrolled in the study, and 531 were randomised to orlistat (n 265) or placebo (n 266). After one year, mean weight loss was signi®cantly greater with orlistat diet compared with placebo diet [control] (5.8% vs 2.3%; p`0.0001). Moreover, twice as many orlistat-treated patients had weight loss of ! 5% (55.6% vs 24.3%; p`0.0001). Total cholesterol was reduced by 1.31% in orlistat recipients compared with a 3.78% increase in control patients (p`0.0001). Similarly, LDL-cholesterol was reduced by 7.09% in orlistat recipients compared with a 0.55% decrease in the control group (p`0.0001). In addition orlistat-treated patients had signi®cantly greater reductions in diastolic BP (75.5 mmHg vs 3.1 mmHg; p`0.01), systolic BP (76.0 mmHg vs 72.3 mmHg; p 0.003), OGTT score (70.37 mmolaL vs 0.09 mmolaL; p 0.014) and fasting plasma glucose levels (70.19 mmolaL vs 0.06 mmolaL; p 0.028). The overall incidence of adverse events was similar in the control and orlistat groups, with the exception of certain gastrointestinal events known to be associated with the inhibitory effect of orlistat on dietary fat absorption. CONCLUSION: This study shows that treatment with orlistat in conjunction with diet can promote signi®cantly greater weight loss than dietary intervention alone in overweight and obese adults at increased coronary risk. This weight loss is associated with improvements in co-morbidities including glycaemic control, cholesterol levels and blood pressure. 
INTRODUCTION:
Type 2 diabetic patients are often obese and can't achieve glycemic control with maximum doses of oral hypoglycaemic drugs. In this study we evaluated the ef®cacy of sibutramine in combination with antiglycemic drugs in obese unregulated type 2 diabetic women. METHODS: Poorly controlled female type 2 diabetic patients who had a hemoglobin A 1c (HbA 1c ) level greater than or equal to 8% randomly assigned to receive placebo or 10 mg twice a day sibutramine in addition to their antiglycemic drugs for 6 months. All of the patients were receiving maximum doses of sulphonylurea, and metformin. 30 patients received sibutramine and 30 patients received placebo. RESULTS: 29 patients in sibutramine group; (one patient was withdrawn, cause hypertension developed) and 25 patients in placebo group (5 patients were withdrawn cause of lack of ef®cacy) completed the study. In sibutramine group, fasting (124,88 AE 8,5 vs 15,76 AE 3,89 mgadl; p`0,0001) and postprandial second hour (102,24 AE 10,40 vs 32,88 AE 6,13 mgadl; p`0,0001) blood glucose, insulin resistance (7,09 AE ,81, vs 31 AE ,28; p`0,0001) calculated by homeostasis model assessment (HOMA), waist circumference (8,04 AE ,69 vs ,92 AE ,49 cm; p`0,0001 ), body mass index (BMI) (3,92 AE ,54 vs ,91 AE ,21 kgam 2 ; p`0,0001), diastolic blood pressure, pulse, lipid pro®le except high density lipoprotein cholesterol and apolipoprotein A1, uric acid, and HbA 1c (2,73 AE ,88 vs ,53 AE ,66%; p`0,0001) dropped signi®cantly more than placebo group. CONCLUSION: The addition of sibutramine to oral hypoglycaemic therapy resulted in signi®cant weight loss and improvement in metabolic parameters. Sibutramine is an effective adjunct to oral hypoglycemic therapy in obese type 2 diabetic patients.
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AIM OF THE STUDY:
To compare the response to sibutramine and placebo in the 4-mo double blind placebo controlled period in obese women participating in a 12 mo multicentric trial of sibutramine in the treatment of obesity (STO). METHODS: Obese women were randomized into placebo group (n 56, age: 45.0 AE 10.7 y, weight 100.2 AE 14.5 kg, BMI: 36.3 AE 4.9 kgam 2 ) and sibutramine-treated group (n 52, age: 43.0 AE 11.5 y, weight 101.1 AE 14.0 kg, BMI: 36.8 AE 4.5 kgam 2 ) which received sibutramine 10 mgad. All patients were adviced to keep 5 ± 6 MJ dietad and increase regular daily physical activity. Regular follow-up was conducted by monthly check-ups. Anthropometry, dietary records, eating behaviour questionnaires, risk factors serum steroids and SHBG and indirect calorimetry were monitored in 4-mo period. RESULTS: 4-mo obesity management resulted in 9.0 kg weight loss in sibutramine-treated group vs. 4.9 kg in placebo group (p`0.001). Percentage of patients losing at least 5% and 10% of baseline weight by wk 16 was signi®cantly higher in sibutramine-treated group than in placebo group (83.7 vs. 41.5%, resp.40.8% vs. 11.3%, p`0.01). Sibutramine induced signi®-cantly higher decrease in waist girth (p 0.026) and sagittal diameter (p 0.015) vs. placebo. A decrease in hunger score which was signi®cantly higher in sibutramine treated group than in placebo group (718.1 vs. 70.7, p`0.0001) positively affected energy intake as assessed by 1-wk dietary record. 4-mo obesity management lead to a higher fat oxidation (as assessed by fasting RQ) in sibutramirie vs. placebo group (p`0.01). Sibutramine treatment induced a signi®cant decrease in serum triglyceride and total to HDL-cholesterol ratio. Drug treatment improved not only eating behaviour. Sibutramine-treated women spent signi®cantly more time by walking than women receiving placebo (153 vs. 110 minawk, p 0.017). Long-term sibutramine treatment positively affected serum insulin, ®brinogen, steroids and SHBG levels. Sibutramine was well tolerated. Among side effects only dry mouth occurred more frequently in drug-treated than in placebo treated subjects (20.4% vs. 5.7%, p 0.027). No signi®cant changes in pulse rate and blood pressure were recorded during the treatment by sibutramine. CONCLUSION: Sibutramine 1) signi®cantly increases weight loss in response to weight reduction regimen in comparison with placebo, 2) positively affects body fat distribution, risk factors, eating behaviour and physical activity, 3) does not induce signi®cant changes in blood pressure and pulse rate. 4) is well tolerated.
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Effect of orlistat on body weight and risk factors in overweight or obese Chinese patients
Shi Yi Fan
1 , and Zhu Jun Ren 2 1 PUMC Hospital, Beijing, China; 2 Shanghai Zhong Shan Hospital, Shanghai, China
INTRODUCTION:
The prevalence of obesity and associated co-morbidities are increasing in China and present a major challenge to physicians. A 6-month multicentre, randomised, placebocontrolled trial was conducted to assess the ef®cacy and safety of orlistat in overweight or obese patients with or without cardiovascular risk factors in China. METHODS: Overweight or obese (BMI 25 ± 40 kgam 2 ) adult patients were eligible with or without at least one of the following risk factors: type 2 diabetes (stable plasma glucose 5.6 ± 12.2 mmolaL), or impaired glucose tolerance (2-h glucose ! 7.8 mmolaL); hypercholesterolaemia (total cholesterol ! 5.2 mmolaL or LDL-cholesterol ! 4.2 mmolaL); or hypertension (diastolic blood pressure 90 ± 105 mmHg). Patients were randomised (2:1) to double-blind treatment with orlistat 120 mg or placebo three times daily in conjunction with a mildly reduced-calorie diet. RESULTS: Of 444 patients recruited, 428 completed the study (orlistat, n 286; placebo, n 142). After 6 months, mean weight loss was signi®-cantly greater with orlistat diet than placebo diet (7.5% [6.1 kg] vs 3.7% [3.0 kg] ; p`0.0001). Over twice as many patients in the orlistat group than placebo group lost ! 5% of their initial body weight (72% vs 32%; p`0.001), while more than ®ve times as many achieved weight loss of ! 10% (26% vs 5%; p`0.001). Orlistat was also associated with a greater decrease in waist circumference compared with placebo (77.2 vs 74.6 cm, p`0.0001). In patients with diabetes or impaired glucose tolerance (orlistat, n 57; placebo, n 28), orlistat resulted in greater reductions than placebo in HbA 1c (70.73% vs 70.08%: p`0.01), postprandial glucose (73.19 vs 70.85 mmolaL; p 0.01) and fasting plasma glucose (72.11 vs 71.01 mmolaL; p 0.004). In patients with hypercholesterolaemia (n 137a66), orlistat was associated with greater reductions than placebo in total cholesterol (71.01 vs 70.63 mmolaL; p 0.002) and LDL-cholesterol (70.47 vs 70.13 mmolaL; p 0.003). In patients with hypertension (n 113a55), orlistat resulted in a signi®cantly greater reduction in diastolic blood pressure (712.5 vs 79.8 mmHg; p`0.05). Orlistat had a similar tolerability pro®le to placebo, with the exception of a higher incidence of gastrointestinal (GI) events. These were generally mild, transient and resolved spontaneously. Only one patient (1a286) withdrew prematurely due to an orlistat-related GI event. CONCLUSION: Treatment with orlistat plus a mildly reduced-calorie diet promotes clinically signi®cant weight loss and improves risk factors in overweight or obese Chinese patients.
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In¯uence of rilmenidine on activity of superoxide dismutase and concentration of malondialdehyde in male obese hypertensive Rilmenidine is a drug with antihypertensive properties which reduce activity of sympathetic system and concentration of catecholamines. It is known that noradrenalin and adrenalin are agents that can induce metabolism and production of free radicals. The aim of the study was access if rilmenidine may impact on antioxidant status in obese. METHODS: We estimated the activity of superoxide dismutase (SOD) in serum (both isoenzimes Mn-SOD and Cu,Zn-SOD) and in erythrocytes (total activity) and also concentration of malondialdehyd (MDA) in serum (secondary product of lipid peroxidation). 23 male obese hypertensive (age 46 ± 80 years, BMI 25,0 ± 37,3 kgam 2 ) were involved in study. Blood were taken before and after about 6,3 months rilmenidine treatment. RESULTS: We observed reduction of total activity of SOD in serum (before: mean 15,89, SD 6,25 NUaml and after 7,89 AE 6,95 NUaml, p 0,002). This decreasing was causing by reduction activity both isoenzimes. Mn-SOD activity decreased from 9,51 AE 4,61 to 4,98 AE 6,25 NUaml (p 0,014) as well as Cu,Zn-SOD from 6,55 AE 4,84 to 2,90 AE 2,56 NUaml (p 0,009).
Activity of SOD in erythrocytes did not change: 10,65 AE 5,46 vs 9,88 AE 5,15 NUamgHb (p 738). We also did not observed any alteration of concentration of MDA in serum (4,13 AE 2,45 vs 2,46 AE 1,68 mmolal, p 0,858).
The changes of SOD activity in serum may be indirect in¯uence of this drug on SOD or it is effect of normalization of activity this enzyme. CONCLUSION: Rilmenidine in obese reduce activity of SOD in serum and do not in¯uence on lipid peroxidation.
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Long term weight loss and maintenance with orlistat and hypocaloric diet in obese patients 
Bondy, France
This multicenter double-blind study is the ®rst to assess the ef®cacy of orlistat in combination with a hypocaloric diet continued for longer than 12 months, thereby evaluating longterm (18-month) weight reduction and maintenance. A total of 696 patients (mean BMI: 36.1 AE 5.8 kgam 2 ) were randomized to orlistat 120 mg tid (O) or placebo (P). Energy intake (EI) was reduced by 20% from run-in period on (never`1200 Kcaladay) and adapted every 4 months from dietary diaries for weight reduction.
Mean EI and fat intake (FI) were comparable in both groups throughout study. Initial observed EI was 2030 AE 480 Kcalad reduced to 1500 AE 360 Kcalad. Fl was reduced from 39 AE 6% to 35 AE 6%. EI and FI remained stable during the study. Patients treated with O lost signi®cantly more weight (kg) than P: initial (97.0 AE 17.3 vs 97.5 AE 17.1, NS), M12 (88.9 AE 16.9 vs 92.9 AE 17.2) and M18 (89.3 AE 17.7 vs 94.0 AE 1 7.9) (p`0.001). After 12 months, 27% of O vs 17% of P patients lost ! 10% of initial weight (p`0.001). Among these 10%-responders, 78% of O patients (73a93) maintained a weight loss over 10% until M18, vs 63% in P (38a60) (p`0.05). Waist circumference (initial O: 105.6 AE 14.6; P: 106.6 AE 14.8 cm, NS) decreased by 6.6 AE 8.5 cm in O and 4.7 AE 7.7 cm in P (p 0.06). Body fat (initial O: 44.5 AE 11.5 kg; P: 44.7 AE 11.9 kg, NS) was reduced by 11.8 AE 14.0% in O versus 5.8 AE 14.3% in P (p`0.001). Only 17 (4.9%) of O patients withdrew because of drug-related adverse events, mainly gastrointestinal.
Orlistat, combined with a hypocaloric diet, has con®rmed its ef®cacy in promoting weight loss and in maintaining body weight reduction throughout 18 months of treatment. ). Plasma mineral and vitamin D content was assessed every two months during weight reduction and a 100 000 U vitamin D dose (Uvedose 2 ) administered per os if levels fell at or below 10 mgal which is the biological safety level in our reference population. Statview 5 (SAS 2 ) was used for statistics and signi®-cance level set at 0,05.
Before Wt loss all plasma Ca and Ph content remained within normal range. 25 OH vit D was`10 mgal in 30% of the subjects and between 10 to 15 mgal in 34%. 25 OH vit D plasma content decreases with pubertal stages in B and G(F(4,150) 3,39 p 0,010) and is higher in caucasians subjects when compared to northern and black africans (F(4,159) 3,43, p 0,010. PTH was elevated in 2 subjects. BMC which increases with pubertal stage (F (4,1) 27,7, p`0,0001) is negatively correlated to plasma 25 OH vit D in B (r 7 0,37, p`0,0005) and G (r 70,40, p 0,005). It is explained by BMI and in boys only by plasrna testosterone concentrations (p`0,0001). A total of 66% of the adolescents had to be supplemented with vit D. Plasma 25 OH vit D content was similar and normal at the end of the Wt reduction in both groups. Vit D suplementation did not exhibit any effect on BMC at the end of the Wt reduction program (F(2,49) 0,13, ns). Vitamin D status has to be monitored in obese adolescents including during Wt reduction and to be better understood in this population.
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Conservative vs surgical treatment in patients of obesity grade IIIpreliminary results of CHARMANT-study Examinational methods were: casual blood pressure, 24-h-blood-pressure, ergometry, parameter of glucose-and fat-metabolism, indirect calorimetry and bio-impedanceanalysis. RESULTS: For both groups all start values did not differ signi®cantly. As a result following signi®cant differences were veri®ed (all data represent conservative vs surgical treatment): Reduction of overweight: 35 vs 48%; 24-h-blood-pressure middle values: 3a0 vs 732a712 mmHg; heart rate: 4 vs 78amin; HbA1c: 725 vs 715%; postprandial insulin-level: 758 vs 742%; basal metabolic rate: 7157 vs 7658 kcalad; LDL: 724% vs 16%. CONCLUSION: Despite of a lower weight reduction all parameters of metabolism improved signi®cantly in the conservative group but not the blood pressure. In the group of complex conservative treated patients the systolic blood pressure increased about 3 mmHg and decreases in the qastric bandic group.
S Klaua
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Early response to orlistat treatment predicts long-term success in overweight and obese patients with co-morbidities
On behalf of the UK Multimorbidity Study Group, Department of Medicine (Diabetes), University Hospital Aintree, Liverpool
INTRODUCTION:
In clinical practice it is desirable to identify early those patients most likely to bene®t from drug therapy. Previous analyses have shown that response to orlistat at 12 weeks predicts long-term ef®cacy in patients with uncomplicated obesity. A clinical trial investigating the ef®cacy of orlistat therapy for weight loss and cardiovascular (CV) risk factor reduction in overweight or obese patients with one or more de®ned risk factors demonstrated that weight loss with orlistat is associated with improvements in co-morbidities. This sub-analysis investigated whether early weight loss predicted long term ef®cacy. METHODS: Overweight or obese adults (BMI ! 28 kgam 2 ) with one or more of the following risk factors were eligible for inclusion: impaired glucose tolerance, hypercholesterolaemia andaor hypertension. After screening, patients entered a single-blind, placebo lead-in period during which they followed a mildly reduced-calorie diet before being randomised to doubleblind treatment with either orlistat 120 mg or placebo three times daily in conjunction with dietary intervention for one year. The study was conducted at 54 primary care centres and 12 secondary care centres in the UK. Responders were de®ned as patients who lost ! 2.5 kg during a 4-week lead-in period and went on to lose ! 5% of their body weight in the ®rst 12 weeks on orlistat. RESULTS: Thirty orlistat-treated patients were classi®ed as responders. Mean weight loss after one year of treatment was 12.3% in the orlistat responder group, compared with 5.8% in the entire orlistat group, and 2.3% in the placebo group (p`0.0001). This marked reduction in body weight observed in the responder group was associated with substantial improvements in other risk factors. LDL-cholesterol was reduced to a signi®cantly greater extent in orlistat responders compared with placebo recipients (712.6% vs 70.6%; p`0.0001). Similarly, total: HDL and LDL: HDL cholesterol ratios were reduced by 9.8% and 14.5% in the responder group compared with 71.7% (p 0.034) and 72.9% (p 0.004) in the placebo group. Glycaemic control was improved in the responder group with reductions in 2-hour postload glucose test and fasting insulin levels of 13.9% (p`0.0001) and 4.1% (p 0.0083), respectively. Signi®cant reductions in diastolic and systolic BP were also observed in the orlistat responder group compared with placebo (712.9 mmHg vs 73.3 mmHg and 712.4 mmHg vs 72.65 mmHg; p`0.001 for both). CONCLUSIONS: Early weight loss with orlistat predicts success in weight loss and improvements in co-morbidities after 1 year in overweight or obese patients with at least one CV risk factor. INTRODUCTION Ð Sibutramine is a combined serotonin and noradrenaline re-uptake inhibitor. Its ef®cacy for the treatment of obesity is partly due to an increase in energy expenditure. In fact, sibutramine stimulates thermogenesis via a selective activation of the brown adipose tissue (BAT). The aim of the present work was to evaluate some morphological aspects and protein expression in the brown (BAT) and white adipose tissues (WAT) of rats chronically administered with sibutramine. METHODS Ð Male adult rats were individually caged and kept at standard laboratory conditions. Nine rats were administered orally with sibutramine at a dose of 9 mgakgadie and six rats were administered with saline (controls). After the treatment, the brown and white adipose depots were carefully dissected for weight and volume evaluations and subsequently processed for morphological and immunohistochemical analyses. RESULTS Ð Sibutramine-treated rats showed a signi®cant reduction in the body weight with respect to the controls. Accordingly, retroperitoneal and epididymal WAT were signi®cantly reduced in weight and volume. No signs of transdifferentiation, that is transformation of white into brown adipocytes, and no differences in the noradrenergic and sensory innervation were found in visceral WAT of sibutramine-treated rats. In the interscapular BAT, both the peroxisome proliferator activated receptor g (PPARg), which strongly drives thè`b rown'' phenotype, and the thermogenic mitochondrial uncoupling protein UCP-1 were more espressed in the brown adipocytes of the sibutraminetreated group. Unexpectedly, in the sibutramine-treated rats the density of noradrenergic innervation was lower then in the controls. On the contrary, the sensory innervation was similar in the two groups. CONCLUSIONS Ð These data con®rm the ef®cacy of sibutramine as antiobesity drug by a reduction of the visceral WAT and a sustained activation of BAT. The mismatch between the high expression of PPARg and UCP-1 and the low density of parenchymal noradrenergic nerves in BAT may be due to a direct peripheral effect of sibutramine andaor active metabolites on an enhancement of noradrenergic stimulus on brown adipocytes.
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A meta-analysis of the effect of infusion of glucagon-like peptide-1 on ad libitum energy intake 
To examine the effect of GLP-1 (7 ± 36) amide on subsequent energy intake by pooling individual subject data from the seven previous studies and from two yet unpublished studies. Raw subject data on BMI and ad libitum energy intake were collected into a common data set (n 115) together with study characteristics such as infusion rate, duration of infusion etc. RESULTS: Energy intake was reduced on average by 727 kJ (95%CI: 548 ± 908 kJ) during GLP-1 infusion. The reduction in energy intake tended to be higher in lean (863 kJ, 634 ± 1091 kJ) than in overweight subjects (487 kJ, 209 ± 764 kJ) (P 0.05). Stepwise regression analysis showed that the GLP-1 infusion rate was the only independent predictor of the reduction in energy intake following GLP-1 infusion (r 0.4, p`0.001). Differences in mean plasma GLP-1 concentration on the GLP-1 and placebo day (n 43) were related to differences in feelings of prospective consumption (r 0.40, p`0.01), fullness (r 0.38, p`0.05) and hunger (r 0.26, p 0.09), but not to differences in ad libitum energy intake. Gastric emptying rate of the meal was signi®cantly lower during GLP-1 infusion compared to saline in studies with measurement of this parameter (n 31). Finally, well-being was not in¯uenced by the GLP-1 infusion. CONCLUSION: GLP-1 infusion reduces energy intake dose-dependently in both lean and overweight subjects. A reduced gastric emptying rate may contribute to the increased satiety induced by GLP-1.
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Ef®cacy of sibutramine for promoting weight loss in the treatment of obstructive sleep apnea ) received SIB (15 mg qd) or placebo in a randomized, double-blind fashion for 6 months. Patients were counseled in diet and weight loss techniques at entry into the study with physician followup visits at 1, 3, and 6 months. Outcome variables included changes in weight, BMI, and AHI (determined by polysomnography at baseline and after 6 months). RESULTS: Twenty patients completed the study. Mean decreases, baseline to 6 months: in weight, SIB 7.5 AE 8.3 kg (P`0.05), placebo 3.9 AE 5.9 kg (NS); in AHI, SIB 3.2 AE 20.4, placebo 2.6 AE 6.6 (both NS). There was a signi®cant correlation (P`0.05) between decreases in BMI and AHI only in the SIB group (Figure) . SIB was well tolerated. CONCLUSION: The results of this study suggest that SIB can be a useful addition to a weight-loss program designed to improve OSA.
RD Ballard
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Effect of orlistat in obese patients with one or more cardiovascular risk factors I Caterson 1 1 on behalf of the Australian and New Zealand Orlistat Study Group. Human Nutrition Unit,DepartmentofBiochemistry,UniversityofSydney,Sydney,Australia INTRODUCTION: A 1-year multicentre, randomised, placebo-controlled study was conducted to assess the ef®cacy of orlistat in obese patients with one or more cardiovascular (CVS) risk factors. METHODS: Obese adults (BMI ! 30 kgam 2 ) were eligible if they had one or more of the following clinically stable risk factors: hypercholesterolaemia (total cholesterol b 5.5 mmolaL andaor LDL-cholesterol b 3.5 mmolaL andaor treated), hypertension (systolic BP b 140 mmHg andaor diastolic BP b 90 mmHg andaor treated), type 2 diabetes (controlled with diet andaor oral agents and HbA 1c 6.5 ± 10%). Patients entered a 4-week single-blind placebo lead-in period, on completion of which they were randomised to double-blind treatment with orlistat 120 mg or placebo tid for 1 year. All patients were prescribed a reduced-fat diet and encouraged to partake in regular exercise for the entire study period. RESULTS: A total of 339 patients were randomised to treatment and eligible for analysis (orlistat, n 170; placebo, n 169). A gender imbalance between treatment groups was apparent at baseline, with a higher proportion of female patients in the orlistat group than placebo group (61.2% vs 52.7%). After 1 year, median weight loss was greater with orlistat than placebo (3.4% vs 0.5%; p 0.001). This weight loss was less than observed in previous orlistat studies and may be attributed in part to prior intensive dietary and behavioural management of known risk factors. Orlistat was also associated with a greater reduction in waist circumference, an effect that was more marked in men than women (75.8 vs 72.4 cm and 74.6 vs 7 1.5 cm, respectively, both p 0.001). There was a signi®cant correlation between weight loss and reduction in waist:hip ratio in the orlistat group (r 0.2; p 0.009) but not placebo group. This correlation was greater in men than women. Improvements in total and LDL-cholesterol, glucose, HbA 1c , insulin and diastolic and systolic blood pressure were signi®cantly greater with orlistat than placebo. More patients in the orlistat group than placebo group were able to reduce the dosages of medications required to control risk factors, while fewer required increased medication dosages. CONCLUSION: Treatment with orlistat is associated with greater weight loss and risk factor reduction compared with placebo in obese patients with one or more CVS risk factors.
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The use of an index to assess the weight reduction ef®cacy of antiobesity agents INTRODUCTION: Categorical analysis is widely used to evaluate the weight reduction ef®cacy of antiobesity agents, dividing the patients in responders or non responders, according to variable criteria of weight loss ef®cacy. Nevertheless, many studies have shown that effectiveness of ancillary therapy strongly affects the result of such evaluation. In some trials, a high percentage of patients from the placebo group may achieve 5% or 10% of weight loss, which may constitute an important confounding factor in ef®cacy evaluation.
WF Coutinho
METHODS:
We developed a very simple index of weight reducing ef®cacy by dividing the percentage of responders in the drug group by the percentage of responders in the placebo group. An Ef®cacy Index (EI) of 2, theoretically indicates that the drug should be expected to double the probability of success for the given population. RESULTS: Data from several trials published in the literature were used to evaluate the ef®cacy index of some antiobesity agents. Obesity clearly has been shown to be an independent risk factor for a variety of diseases, including cardiovascular disease. Numerous studies have shown that modest weight loss is associated with reduced blood pressure, improved insulin sensitivity and glycaemic control, and a less atherogenic serum lipid pro®le. Pharmacological therapy has been proposed as an adjunct to diet and lifestyle changes to improve long-term weight loss. Orlistat promotes weight loss by inhibiting gastrointestinal lipases, thus lowering absorption of dietary fat, on average by 30% with a dose of 120 mg three times a day. The oxidative stress increases in obese patients. The high-density lipoprotein associated paraoxonase activity can inhibit low-density lipoprotein oxidation and has an antiatherogenic effect. OBJECTIVE: to examine the ef®cacy and tolerability of orlistat in promoting weight loss and to assess effects on lipid pro®le and serum paraoxonase activity. METHODS: 25 patients were involved in the study (18 males, 7 females). The mean age was 48.1 AE 10.3 y. The effects of daily 3Â120 mg orlistat (Xenical 1 ) on BMI, waist circumferences, serum cholesterol, triglyceride, apolipoproteins were determined. The serum paraoxonase activity was measured spectrophotometrically using paraoxon as substrate. RESULTS: It was observed, that after a six month treatment with orlistat the BMI (p`0.001) and waist circumferences (p`0.001) were reduced signi®-cantly. The serum triglyceride and cholesterol levels are decreased (721,82%, 73.65% respectively), while the protective high-density lipoprotein was increased by 11%. The low-density lipoprotein decreased by 75.4%. Apolipoprotein B-100-, apolipoprotein A1 levels were unchanged. Both the serum paraoxonase activity (103 AE 42 Ual, vs. 116 AE 54 Ual, p`0.05) and the standardized values for HDL (PONaHDL) were signi®cantly increased (from 75 AE 21 to 84 AE 25, p`0.05) while the PONaapoA1 ratio did not change signi®cantly. CONCLUSION: The six month treatment with daily 3Â120 mg orlistat is thought to normalize the lipid pro®le and improve the antioxidant status by increasing serum paraoxonase activity in these patients.
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Echocardiographic and electrocardiogra®c changes after treatment of rilmenidine in obese hypertensive 
METHODS:
The study was aimed to compare echocardiographic and electrocardiographic parameters in 29 males before and after 6 months rilmenidine treatment (mean age 57,8 SD 9,9 years, BMI 30,0 SD 4,0 kgam 2 ). By echocardiography was estimated: ejection fraction (EF), end-systolic and end-diastolic dimension (LVDd, LVSd), right ventricular diameter, posterior thickness, intraventricular thickness, left atrium diameter (LAD), aortic diameter (AoD), left atrium area, right atrium area. By ECG we measured R amplitude in I-III, aVF, V 5 , V 6 , S amplitude in III, V 1 , changes of P and T wave, interval of QT, Cornel Index (CI), Lyon (Sokolow) Index (LI). 
RESULTS:
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The impact of sibutramine on insulin resistance and metabolic parameters 
MA Tambascia
Service of Endocrinology -State University of Campinas (UNICAMP) -13083-970 -Brazil
Obesity is associated to insulin resistance with a strong impact on cardiovascular risk factors. Weight loss can restore normal metabolic aspects but there are few data about the in¯uence of the medical treatment on it. This was a double blind, placebo controlled, prospective study with a follow-up of 6 months to compare the effect of sibutramine (10 mgaday) on insulin resistance and metabolic parameters. We selected 40 obese patients (BMI: 34.6 AE 2.9 kgam 2 ), 39 women and 1 men, age of 40.3 AE 10.0 years. They were evaluated before and 6 months after the study using anthropometrical data, blood pressure, bioimpedance, sensitivity to insulin (Kitt), Homeostasis Model Assessment (HOMA) to analyze insulin resistance and beta cell secretion, lipid pro®le, uric acid. 17 patients using Sibutramine and 14 on placebo completed the study. In placebo group we observed an increase of 1.2% of body weight and a reduction of 6.1% in Sibutramine group. The use of sibutramine was associated to alteration in glucose levels (76.3x 3.3%), HDL-cholesterol ( 2.6x72.5%), triglycerides (723.1x 8.2%), gamma-GT (714.9x71.0%) and leptin (714.7x76.7%). It was also evident an improvement of insulin sensitivity and a reduction of 23.1% of HOMA-ir with an increase of 12.3% in placebo. HOMAbeta reduced by 26.4% and increased by 13.4% in placebo. In conclusion Sibutramine was quite effective in reducing insulin resistance and has an effect in sparing insulin secretion.
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The effect of moderate weight loss on echocardiographic parameters in obese women treated with sibutramin Z Sido Â in Hungary in 1999, 37% of the adult population is overweight while 23% is obese. In the former study the authors concluded that severe obesity that had been present for a longer period put a great load on the heart and induced eccentric left ventricular hypertrophy resulting eventually in diastolic dysfunction in spite of an intact systolic function. METHODS: Twenty-one middle aged (average 44 year), obese women (BMI 31.7 kgam 2 ) participating in the program were kept to a 1000 ± 1300 Caladay diet divided into 4 ± 5 daily meals during the halfyear study period. Physical exercise was usually performed at medium intensity 3 ± 4 times per week. The authors intended to investigate the effect of 10 mgaday sibutramin, which is applied in the complex treatment of obesity. Echocardiographic examinations using a Vingmed System V device were performed on two occasions between July 1999 and May 2000. RESULTS: The average 5.1 kg weight loss developed after six months had passed. This weight loss was 5.9% of initial body mass and was strongly signi®cant. From the left ventricular morphologic parameters, wall thickness showed a more marked decrease than LVIDD did; IVSDT and LVPWDT were diminished by 8.4 and 8.2%, respectively, while the decrease of LVIDD was only 3.5% and statistically not signi®cant. Calculating from these two compo-nents, LVM displayed a very marked difference: a decrease of 18.8%, the greatest change among the morphological parameters. LVLDD decreased very slightly (4.1%). Similarly slight but signi®cant reductions were seen in the left atrial diameters measured in the parasternal and in the longitudinal views and in the RAD, representing 4.6, 6.0 and 2.0%, respectively. Were observed a marked, signi®cant increase (11.7%) in the early diastolic peak velocity (E), a slight, non-signi®cant decrease in the late diastolic peak velocity (A). As the result of these changes, EaA ratio displayed a very marked, signi®cant increase (16.4%). The echocardiographic examinations did not reveal valve-deformities or abnormal¯ow in any cases, either at the ®rst, or the second examinations. CONCLUSION: Data of the present study indicate that the half-year life-stylemodi®cation program with sibutramin brought about not only a marked weight loss, but also a signi®cant improvement in both the morphological and functional characteristics of the heart. Sibutramin may also play an advantageous role in the complex management of obesity, assisting in the achievement of long lasting and moderate weight reduction. ; body weights ranged from 110.78 to 117.38 kg. Change in weight from randomization to twelve weeks was analyzed for trend and subsequently for each dose group versus placebo on the Completer (C) and the Last Observation Carried Forward (LOCF) data set.
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Subjects lost weight in all drug treated groups while the placebo subjects gained 0.6 kg and 0.3 kg, respectively (C and LOCF, respectively). The optimal dose of AXOKINE of 1 mgakg resulted in a weight loss at week 12 of 4.6 kg (C) or 3.7 kg (LOCF) relative to placebo (p for both analyses 0.0001). All drug groups were statistically signi®cantly different from placebo. In general, AXOKINE was well tolerated. Most frequently reported adverse events included injection site reactions, nausea, cough and headache. Nausea was recorded most frequently at the 2 mgakg dose (9a33 subjects). Cough was increased above background only at the 2 mgakg dose (13a33 subjects). Routine safety laboratory values and vital signs were not affected by the drug. These 12-week results in obese humans con®rm earlier experiments in rodent models of obesity. In this study, AXOKINE was well-tolerated and led to signi®cant weight loss in severely and morbidly obese humans. Further studies will establish the long-term safety and ef®cacy of this promising weight loss compound.
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Propranolol increases the weight gain during antithyroid treatment
G Mardarowicz
1 , and J Lopatyn Â ski
Medical University in Lublin, 20-081 Lublin, Poland
INTRODUCTION:
A long term prospective follow up study performed by us on a cohort of 300 thyrotoxic patients during antithyroid treatment and during return of euthyreosis revealed signi®cant weight gain and development of glucose intolerance, hyperinsulinaemia, hypertension and dyslipidaemia. In search for factors implicated in development of polymetabolic syndrome in patients with history of antithyroid treatment we analysed the in¯uence of chronic use of Propranolol on body weight changes and insulin resistance-related concomitant metabolic disorders. METHODS: We chose two groups of patients from the cohort: I ± of 18 patients treated only with methimazol during a period of at least 6 ± 12 months, II ± of 35 patients treated continuously with methimazol and propranolol over a period of at least 6 ± 12 months. In both groups the mean age, initial body weight and severity of thyrotoxicosis assessed by Crooks' Index and serum triiodothyronine concentration were comparable. In all patients we investigated body weight, serum lipids, fasting blood glucose and fasting serum insulin before treatment and in 2nd, 5th, 10th year of follow-up. To assess the insulin resistance we used a simple fasting insulin resistance index (FIRI) by Duncan.
RESULTS:
The initial body weight in group I was 60.1 AE 8.8 kg and in group II 760.7 AE 11.3 kg. The increase of body weight in group I in 5th year of followup was 78.8 AE 7.8 kg and in group II 710.4 AE 5.9 kg and in 10th year 79.6 AE 7.7 kg and 13.8 AE 10.5 kg respectively. 2 patients (11.1%) of group I and 6 patients (17.1%) of group II developed diabetes mellitus during the ®ve-year-long observation. The mean value of FIRI in 5th year of follow-up was 31.1 AE 3.2 in group I and 36.9 AE 4.8 in group II. CONCLUSION: Our results con®rm the observations known from studies of hypertensive patients that long-term use of beta blockers results in weight gain even after cessation of this therapy. This suggests that in thyrotoxic patients prone to insulin resistance, beta blockers should be used only as a short7term treatment at the beginning of the antithyroid treatment.
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Evaluation of the safety and ef®cacy of sibutramine, orlistat and metformin in the treatment of obesity INTRODUCTION: Previously, we observed that some obese patients receiving 10 mgaday sibutramine felt hunger at night, and cause of that we planned this randomized, prospective clinical trial to study the ef®cacy and safety of sibutramine 10 mg bid and compare with the effects of orlistat 120 mg bid and metformin 850 mg bid. METHODS: 150 female patients with a body mass index (BMI) greater than 30 kgam 2 were included. The subjects were outpatients attending to Baskent University Endocrinology and Metabolism Clinic. They were randomized into sibutramine 10 mg bid (group 1; n 50; mean age 42.27 AE 1.40 years), orlistat 120 mg tid (group 2; n 50; mean age 42.13 AE 1.32 years), metformin 850 mg bid (group 3; n 50; mean age 43.58 AE 1.40 years). All patients received medications for 6 months. 2 patients from sibutramine and 2 from orlistat group were withdrawn from the study cause of side effects. RESULTS: At the end of the study, sibutramine, orlistat and metformin showed a signi®cant decrease in BMI (13.57, 9.06 and 9.90%); waist circumference (10.43; 6.64 and 8.10%), fasting and postprandial blood glucose, insulin resistance assessed by HOMA (38.63; 32.73 and 39.28%), total cholesterol, low density lipoprotein, very low density lipoprotein cholesterol, triglyceride, lipoprotein (a), apolipoprotein B, uric asit, pulse, systolic and diastolic blood pressure; but high density lipoprotein cholestrol and apolipoprotein A1 levels didn't change in all groups signi®cantly. In sibutramine group BMI decreased signi®cantly more than metformin and orlistat groups (p`0.0001). In multivariate analysis only metformin decreased HOMA signi®cantly independent of weight loss (p 0.08); neither sibutramine nor orlistat did show any signi®cance. CONCLUSIONS: Results of this study con®rms that all three medications are effective, safe, reduce cardiovascular risk factors and can decrease the risk of type 2 diabetes mellitus in obese females. Also shows that sibutramine 10 mg bid is more effective than orlistat and metformin, and metformin improves insulin sensitivity independent of weight loss.
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Weight gain and serum insulin levels in epileptic patients with valproic acid therapy
G Luef
1 , I Abraham 1 , E Trinka 1 , G Bauer 1 , F Hoppichler 1 , and M Lechleitner INTRODUCTION: Antiepileptic drug therapy with valproic acid (VPA) was described to be associated with an increase in body weight. VPA as a fatty acid derivative might be of complex in¯uence on insulin resistance. Considering the long treatment period of antiepileptic therapy this relationship of VPA with insulin resistance could increase the cardiovascular risk.
METHODS:
We have studied clinical and laboratory effects of antiepileptic therapy in 22 female patients treated with VPA (mean age 31.3 AE 4.2 years) and in 21 female patients under carbamazepine or lamotrigine monotherapy (mean age 32.3 AE 5.6 years). All study participants underwent an oral glucose tolerance test. RESULTS: Mean body mass index in the VPA group (25.1 AE 3.6 kgam 2 ) was higher than in the control group (23.9 AE 3.7 kgam 2 ), and the fasting and postprandial serum leptin levels were found to be increased (17.3 AE 15.8 ngamL and 16.2 AE 15.8 ngamL vs. 10.8 AE 8.0 ngamL and 9.3 AE 7.4 ngamL). While plasma glucose, lipid levels, fasting insulin and Cpeptide levels did not differ between the study groups, postprandial insulin Track 8 Pharmacological treatment S111 levels were found to be signi®cantly higher in the VPA than in the control group (48.5 AE 25.5 mUamL vs. 34.1 AE 17.2 mUamL; p`0.048), which could also be observed for the postprandial proinsulin values (52.5 ± 30.2 pmolaL vs. 29.5 ± 12.0 pmolaL; p`0.017). CONCLUSIONS: Our data indicate that the fatty acid derivative VPA increases glucose stimulated pancreatic insulin secretion which could be responsible for the observed increase in body weight. We have investigated the effects of Conjugated Linoleic Acids (CLA) on energy metabolism in adult male Golden Syrian. The animals were assigned to either a standard diet (Control group) (33% of energy from lipids, 49% from carbohydrates, 18% from proteins) or to the same diet augmented with CLA isomers: 1.6% of energy as rumenic acid (Rumenic group), or 1.6 % as rumenic acid and 1.6% of the l0t, 12c-CLA isomer together (CLA mix group). In a ®rst experiment, basal energy expenditure, thermic effect of feeding, thermic effect of spontaneous activity as well as the relative oxidation of glucose and lipids during these processes were studied by indirect calorimetry. In a second experiment, energy expenditure, glucose and lipid oxidation, were measured during a 2 hour exercise at 60% of VO 2 max on a treadmill. At the end of the study, body composition was analysed by dissection and weighing of the weight of the main tissues and organs.
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No difference in body weight and body composition were observed between the three groups at the end of the study although the CLA mix-treated group exhibited less body triglyceride accumulation over time (in vivo NMR determination). The lack of effect of the CLAS was associated with the absence of any signi®cant effects on basal metabolic rate, thermic effect of food, thermic effect of activity, and variations in lipid oxidation during activity and feeding, despite carnitine palmitoyltransferase activity, the rate-limiting enzyme committed in fatty acid oxidation, was increased in liver and red muscle tissues.
In conclusion, contrary to what can be observed in other species, in particular mice, hamsters like humans, do not seem to be very responsive to a CLA supplementation. The reason(s) for the important difference observed between species remains to be understood and may help to improve the effects of CLAs on non response species.
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The experience of a weight management clinic in a district general hospital ± the use of orlistat 
INTRODUCTION:
In the UK, obesity as de®ned as a body mass index above 30 kgam 2 is reaching epidemic proportions with 16% of men and 17.3% of women affected. Obesity (particularly abdominal obesity) is associated with insulin resistance, various metabolic abnormalities and signi®cantly increased risk of diabetes and atherosclerosis. Orlistat, a pancreatic lipase inhibitor, represents a new class of anti-obesity drug. In June 1999 we set up a pilot weight management clinic at our district general hospital to help address these issues.
METHODS: Obese patients (BMI b 30 kgam
2 ) with co-morbidities who had failed at previous weight loss initiatives were recruited from various hospital clinics. After initial assessment and a 4-week run-in period, suitable patients were commenced on orlistat (120 mg taken three times daily with food). Dietetic reviews were carried out every 4 weeks with medicaladietetic reviews every 12 weeks. RESULTS: We have now recruited 102 patients into the programme. Fortyfour of these patients (15 M, 29 F) have completed at least 3 months treatment with orlistat. After three months six patients (14%) defaulted from the clinic. Weight at commencement of orlistat therapy was 123.1 AE 23.9 kg (mean AE SD) and BMI 44.3 AE 7.9 kgam 2 . The weight loss achieved is detailed in the table below: CONCLUSION: It is possible, in the setting of a busy district general hospital, to effect signi®cant weight reduction in obese patients with use of a structured weight management programme using orlistat.
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Ef®cacy and safety of orlistat plus a reduced-calorie diet in obese nondiabetic patients: a 1-year Austrian multicentre study H Toplak 1 1 on behalf of the Austrian Orlistat Study Group, Medizinische Universita Ètsklinik, Karl-Franzens-Universita Èt Graz, Graz, Austria
INTRODUCTION:
The ef®cacy and safety of orlistat in overweight or obese, non-diabetic patients were assessed in a 1-year study. METHODS: Overweight or obese (BMI 28 ± 45 kgam 2 ), non-diabetic patients aged 19 ± 65 years were recruited at 8 centres in Austria. Patients entered a 4-week single-blind placebo plus reduced-calorie diet (600 kcal daily de®cit, $ 30% of calories as fat) lead-in period, those achieving weight loss of b 2 kg being randomised to double-blind treatment with either orlistat 120 mg or placebo tid plus diet for 24 weeks. Patients who completed the double-blind treatment phase and who were willing to continue entered a 24-week openlabel orlistat plus diet extension phase. RESULTS: A total of 291 patients entered the lead-in period, of whom 251 were randomised to treatment (orlistat, n 126; placebo, n 125). Ninetyone patients in the orlistat group and 90 in the placebo group consented to enter the open-label extension phase. During the lead-in period, mean body weight decreased in both the orlistat (104 to 100 kg) and placebo (102 to 98 kg) treatment groups. Weight loss continued during the double-blind treatment phase and, after 24 weeks, median weight loss was signi®cantly greater in the orlistat group than placebo group (74.2 vs. 72.4 kg; p 0.003). More patients in the orlistat group than placebo group achieved weight loss of ! 5% or ! 10% after 24 weeks (54% vs. 37% and 20% vs. 13%, respectively). Between-group differences in weight loss markedly differed between study centres, possibly as a result of dissimilar patient management andaor compliance. Compared with placebo, orlistat was also associated with greater reductions in median waist circumference (74 vs. 72 cm; p 0.006) and subscapular (76.7% vs. 73.2%) and triceps (77.3% vs. 73.7%) skinfold thicknesses. In the open-label extension phase, patients previously treated with placebo showed a tendency to additional weight loss with orlistat (94.2 to 93.2 kg). No further weight loss was observed in patients previously treated with orlistat (94.9 kg to 94.6 kg). Orlistat was well tolerated. Adverse events were more frequent in the orlistat group than placebo group in the double-blind treatment phase due to a higher incidence of gastrointestinal (GI) events (n 38 vs. 9) related to the inhibition of dietary fat absorption by orlistat. In the open-label extension phase, orlistat-related GI events were more frequent in patients previously on placebo than in patients previously on orlistat (n 15 vs. 4), suggesting improved compliance with a reduced-fat diet in patients treated with orlistat. CONCLUSION: Orlistat plus a reduced-calorie diet is effective and safe in the treatment of overweight or obese non-diabetic patients.
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Orlistat improves insulin sensitivity in obese subjects irrespective of their weight loss rate Obesity is associated with insulin resistance.
The aim of the present study was to investigate postprandial hyperinsulinemia in obese patients aged 18 ± 29 years receiving Orlistat (XENICAL) and showing different weight loss rate during the treatment.
Only female obese subjects were included in the study. The course of treatment duration was 6 months. Group 1 (n 7; BWI 34.6 AE 4.14 kgam 2 ) was composed of obese patients with weight loss rate up to 7 kg (4.8 AE 1.2 kg on average) for a 6-months treatment with Orlistat. Group 2 (n 7; BWI 37.6 AE 7.16 kgam 2 ) consisted of obese subjects with weight loss rate from 9 to 16 kg (11.0 AE 3.3 kg on average) for the same treatment period. Body weight index (BWI), basal (a) and postprandial (B) insulinemia (B mUaml) were measured in all patients at carrying out standard glucose tolerance test before and after treatment with Orlistat. CONCLUSION: The administration of Orlistat improves insulin sensitivity in obese subjects irrespective of weight loss rate. Weight loss rate during treatment with Orlistat does not depend on the initial body weight and the level of basal hyperinsulinemia. The initial postprandial hyperinsulinemia does not determine the weight loss rate.
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A randomised trial on weight maintenance including a low-fat aromatic gastronomy course
S Bakhùj
1 , C Meyer Nielsen 1 , S Toubro 1 , and A Astrup INTRODUCTION: Weight maintenance after weight loss is generally not very successful in obese subjects. Adherence to a low-fat diet and increased physical activity can improve weight maintenance but still many subjects regain weight. We hypothesised that improved sensoric properties of the low fat diet may improve weight maintenance. METHODS: Forty-one obese subjects (age 40 AE 9, BMI 34 AE 4.22a19 (femaleamale)) all underwent 12 weeks energy restriction and treatment with orlistat. Subjects who achieved at least 8% weight loss during the 12 weeks entered a 2nd phase where they all received intensive dietetic counselling but randomised into either an additional course of low-fat aromatic gastronomy or a neuro-linguistic programming (NLP) program, both lasting 4 months.
RESULTS:
The weight loss during phase one was 9.7% and 10.0% of the initial body weight, in the groups subsequently randomised to NLP and gastronomy course, respectively (NS). During the 2nd phase the NLP lost an additional 1.1% of the initial weight, whereas the gastronomy group remained weight stable. After phase 2 body fat mass (FM) was reduced by about 13% in both groups (NS).
CONCLUSION: The study demonstrate that short-term weight maintenance is not impaired by replacement of NLP therapy by a low-fat aromatic gastronomy course in obese subjects. Long term maintenance and quality of life will be assessed in this study.
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Importance of patient support programmes in weight management with orlistat The decision to prescribe orlistat was based on weight loss during an initial 4 week lead-in period. Nine subjects dropped out before a decision to prescribe orlistat was made, and 7 subjects dropped out at 4 weeks. A further 3 patients who met the criterion of 2 kg weight loss in the 4 week leadin did not receive orlistat. (Total 19, BMI 37.8 AE 5.9, range 29.2 ± 57.9). Orlislat was prescribed to 27 patients, (BMI 42 AE 9.7, range 31.5 ± 62.1). Nine patients failed to lose 2 kg, but were offered and accepted orlistat. At 3 months the average weight loss was 3.6% in the orlistat group and only 0.2% in those that remained of the control group. Those gaining weight had orlistat discontinued. Weight loss after 6 months was 5.3% in the orlistat group after, versus 2.6% in the control group. Those who lost 5% or more at 3 months had a strong tendency to continue weight loss through to 6 months (n 5 mean wt loss at 3 mths 7.3 AE 2.1% vs. mean wt loss at 6 mths 10.8 AE 5.1%, p 0.09) and had a lower prognostic motivation score than those who did not achieve this weight loss (motivation score 5.8 AE 1.6 vs. 8.0 AE 1.7; p 0.05). There was no correlation between extent of weight loss in the lead-in period and weight loss after 13 weeks of orlistat treatment. CONCLUSIONS: Despite intensive dietetic support, weight loss, even with orlistat, is modest. Orlistat therapy after 3 months should be reserved for those that have lost at least 5% body weight. 
P Andersson
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is associated to a reduced calorie diet (1300 ± 1600 Kcal, 20 ± 25% of energy intake from fat) and to dietary and behaviour counselling. In each group of patients a signi®cant weight loss is observed in each period examined. Interestingly weight loss percentage decrease observed during the last 3 months of treatment seems signi®cantly higher in patients of group A than in patients of group C. If this signi®cative difference will be proved at the end of the prospective study, it could be simply due to BMI differences between groups. Another possible explanation is that in patients taking orlistat, dietary fat excess induces remarkable gastrointestinal side effects, which allows the patient to follow the diet in a more correct way. This is probably more evident in those subjects affected by morbid obesity (BMI ! 40) merely because they tend to assume high doses of fats in the diet. INTRODUCTION: Pharmacological therapy of obesity is more frequent prescribed as an adjunct to diet and lifestyle changes to improve long term weight loss. Its ef®cacy, tolerability and safety-pro®le should be proved by clinical trials. OBJECTIVE: The aim of the study was to evaluate the ef®cacy, tolerability and safety-pro®le of sibutramine (Reductil) in promoting weight loss over a 6 months period. PATIENTS AND METHOD: The study included 50 patients according to the following inclusion criteria: age between 18 ± 65 years, Body Mass Index (BMI) b 30 kgam 2 , failure of previous weight loss attempts. The study has been designed as``intention to treat'', duration of treatment ± 24 weeks, monthly monitoring, with complete clinical and biochemical patient evaluation at baseline (V1), at 12 weeks (V7) and the end (V13). Daily sibutramine dose ± 10 mgaday and hypocaloric diet. Demographic data: age ± 37.52 AE 9.64 years, 72% females. Baseline anthropometric data: weight ± 97.17 AE 16.67 kg, waist circumference 96.58 AE 9.94 cm (females), 116.71 AE 10.48 cm (males), BMI ± 33.94 AE 3.86 kgam 2 . Baseline clinical data: systolic blood pressure (SBP) ± 125.20 AE 12.6 mmHg and diastolic blood pressure (DBP) ± 77.20 AE 9.37 mmHg. Baseline biochemical data: glycaemia ± 93.22 AE 9.39 mgadl, total cholesterol ± 194.28 AE 31.80 mgadl, tryglicerides ± 169.32 AE 67.71 mgadl, HDL-cholesterol ± 37.14 AE 7.97 mgadl. RESULTS: Anthropometric data: weight ± 84.30 AE 16.77 kg, waist circumference ± 86.08 AE 9.18 cm (females), 111.28 AE 10.95 cm (males), BMI ± 29.6 AE 3.77 kgam 2 . Baseline clinical data: systolic blood pressure (SBP) ± 122.10 AE 8.21 mmHg and diastolic blood pressure (DBP) ± 74.30 AE 6.85 mmHg. Baseline biochemical data: glycaemia ± 86.18 AE 8.76 mgadl, total cholesterol ± 183.60 AE 27.53 mgadl, tryglicerides ± 149.82 AE 64.42 mgadl, HDL-cholesterol ± 41.52 AE 7.71 mgadl. Mean total weight loss ± 13.60 AE 12.18 kg. Tolerability: very good ± 46 patients (92%) and good ± 4 patients (8%), mild side effects in 3 patients: dry mouth, insomnia. Ef®cacy: very good ( b 2 kgamonth) ± 26 patients (52%), good (1.5 ± 2 kgamonth) ± 18 (36%) and satisfactory (`1.5 kgamonth) ± 6 patients (12%). CONCLUSION: Sibutramine (Reductil), 10 mgaday, in conjunction with an appropriate hypocaloric diet, promotes clinically signi®cant weight loss, with a good tolerability. 
School of Medicine -State University of Campinas, SP -Brazil
Superobesity is a clinical therapeutic challenge, but bariatric surgery has been considered a convenient treatment approach. Massive weight can cause metabolic abnormalities and also increase risks for obese patients indicated to be submitted to a weight reduction surgery. There is few experience about the use of sibutramine to treat superobesity. The aim of this study was to evaluate the ef®cacy and the adverse effects of sibutramine in superobese patients before undergoing to bariatric surgery. We prescribed 15 mg of sibutramine to 20 superobese patients three months before they were scheduled to surgical procedure. Anthropometrics measures, abdominal circumference (AC), blood pressure (BP), heart rate (HR) and most common adverse complaints were evaluated at baseline and during 3 months.
The use of sibutramine induced a weight loss around 7% after three months of treatment. The drug was well tolerated by patients and there were not signi®cant adverse reactions. We speculate that sibutramine can be use to reduce weight and surgical risks in superobese patients selected to undergo to bariatric surgery. Long term utilization of sibutramine as well as the metabolic changes in this population remains to be study.
Weight loss during the ®rst 4-weeks was positively correlated (p`0.02) with total weight loss after 6-m treatment. There was no withdrawal from the study and all patients had a high and stable compliance during the study. 20% of patients had reversible gastrointestinal events.
Body composition assessment has been done by DXA (Lunar DPX-L). Total fat was signi®cantly reduced (711.6%). Changes in abdominal fat (% of total fat) and total lean mass (kg) were not statistically signi®cant. In conclusion, orlistat as an adjunct to dietary intervention promotes weight loss and improves cardiovascular risk factors in obese patients.
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Sibutramine and hormonal activity E Pucci 1 , and R Valeriano 1 1 Dipartimento di Endocrinologia Sezione di Endocrinologia University of Pisa INTRODUCTION: Sibutramine (SB Reductil-Knoll) is a novel antiobesity agent that acts centrally as a serotoninergic (5-HT) and noradrenergic (NE) reuptake inhibitor. It reduces body weight by enhancing satiety and stimulating thermogenesis. It is well known that neurotrasmitters are involved in the central control of the hormonal secretion through the hypothalamic-pituitary system. Among the other neurotransmitters 5-HT and NE are involved in the release of gonadotropins (LH and FSH) as well as other pituitary hormones as growth-hormone (GH) prolactin (PRL) and thyroid-stimulating-hormone (TSH). Even the hypothalamic-pituitary-adrenocortical (HPA) activity seems to be controlled by catecholaminergic and serotoninergic neurotrasmission. The goal of our paper was to evaluate the response of the endocrine system to a single Sibutramine administration (10 mgaos). PATIENTS AND METHODS: Eight healthy markedly obese caucasian females (BMI b 35) aged from 25 to 36 were studied. We evaluated basally circadian rithm of cortisol and ACTH and free urinary cortisol. The patients underwent, in a precocious follicular phase of the menstrual cycle, a pulsatily study for LH and FSH (4h sampling every 10 min starting from 8 am) and a standard GnRH test (10 mg in i.v. bolus at the end of the pulsatile period). At the same times GH, TSH and PRL were evaluated. To study gonadotropin pulsatile activity DETECT program was used. Fortyeigth hours after, evaluations were repeated following SB administration (7ahaam).
RESULTS AND CONCLUSIONS:
The activity of all studied hormones was basally in the normal range and remained unchanged after SB administration. Even episodic LH secretion showed no signi®cant differences in terms of pulse frequency and amplitude before and after the drug. The LH response to GnRH was similar (UCA 985 AE 180 before and 1148 AE 220 P NS) After SBadministration). The GH plasma levels were basely lower than in normoweight subjects, as expected, and showed no difference in the secretory pattern before and after sibutramine administration in six of our patients. Two of the studied subjects demontrated unexpected incresase of plasma GH ( from 0.2 AE 0.02 to 2.8 AE 0.9 ngaml), starting from the 40th minute up to the 160th minute. Our experience underline that, under the neuro-endocrinological point of view, SB even been a serotoninergic-noradrenergic drug, can be considered as a safe drug with no relevant effets on hormonal secretion eaor activity.
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Sibutramine on the treatment of hypertensive, overweight patients
